Global Regenerative Group

Global Regenerative Group Global Regenerative Group invests, identifies, develops and markets groundbreaking medical technologies related to Regenerative Medicine, globally!

Global OrthoBiologic is a privately-held groundbreaking medical technologies’ company for use in therapies that significantly enhance the body’s natural healing ability. The company has developed extensive experience in the most advanced medical device industries. In the past several years, the emphasis has been focused exclusively on Regenerative Medicine and stem cell technologies, products, and

therapies. The technologies for stem cells are cutting edge, safe, clean and do not use any additives, enzymes, or require culturing or growing of cells. Global OrthoBiologic consults with medical technology companies that are startups and/or companies looking to expand and grow their business. Global OrthoBiologic has built a comprehensive network of experts in Europe, South America, Middle East, Asia, and Australia. The company partners with recognized medical facilities worldwide for evidence-based clinical medicine. Global OrthoBiologic subsidiary Global ACADEMY, therefore, provides educational events allowing physicians and healthcare practitioners to expand their knowledge of best practices and clinical applications of regenerative medicine in stem cell and gene therapy, novel biotechnologies, and tissue engineering. Global ACADEMY provides training workshops consisting of lectures and hands-on practicum to mentor physicians and healthcare professionals in best practices and standardized methods for optimal results and better patient outcomes. Additionally, larger, international conferences are provided in various locations to provide opportunities for physicians to learn new information and relevant protocols that impact their work while creating an occasion for networking with highly respected and esteemed international thought leaders with clinical experience in a variety of specialties. Educational information is provided to physicians both at sponsored events as well as through Global ACADEMY’s digital websites, physician portal, newsletters, email content, and social media. Membership in Global ACADEMY is available for healthcare professionals interested in up-to-date information about novel therapies, innovative technology, specialized protocols and best clinical translation practices. Global OrthoBiologic holds exclusive distribution rights for various medical devices, topical skin care products, food supplements, biotechnologies and gene therapies in the International markets OUS, as well as other jurisdictions, with a steady stream of products in the pipeline through our Global Life subsidiary and Global partners. Global OrthoBiologic’s current focus is in Europe, Middle East and Asia; however, Global OrthoBiologic is quickly expanding its reach through collaborations with international companies and academic institutes. Global OrthoBiologic, therefore, is cognizant of the regulatory status of various countries and seeks to spotlight various regulatory governments open to regenerative medicine. Global LIFE is a subsidiary involved in regenerative medicine research for auto-immune disorders, chronic pain, injuries, Alzheimer’s disease and cancer. These goals require Global LIFE to search for funding in order to maintain these programs and provide better patient options and outcomes for difficult diseases. Finally, Global ACADEMY provides access for its membership and those within the healthcare industry to participate in events focused on diseases due to aging. Using various anti-aging strategies, Global ACADEMY collaborates with educational institutes, regenerative medicine companies and governmental bodies to globally impact patients through anti-aging medicine Regenerative Medicine, allowing them to live a better quality of life as they advance in years. What separates Global OrthoBiologic from the competition? Other companies would believe that once a distributor is selected, the job is done. However, Global OrthoBiologic knows that the job has only just begun. Once the selection process is completed, the company ensures that all the necessary support is provided to our exclusive distributor for success in the host market.

The future of regenerative medicine is here 🧬Introducing liposmart® UFAT — Unified Fluid Adipose Tissue - A next-generat...
05/29/2026

The future of regenerative medicine is here 🧬

Introducing liposmart® UFAT — Unified Fluid Adipose Tissue - A next-generation approach designed to harness the body’s own regenerative potential through minimally manipulated adipose tissue.

🔬 Mechanical processing — no enzymes involved
⚡ Same-session application — no laboratory required
🛡️ 100% autologous — using the patient’s own tissue
✨ Preservation-focused processing — maintaining key regenerative components
Science-driven. Clinically practical. Naturally regenerative.

👉 Bring UFAT into your practice — link in bio.

30 Trillion Reasons Your Skin Heals 🙌Exosomes are 30-150nm extracellular vesicles that regulate: → Fibroblast proliferat...
05/28/2026

30 Trillion Reasons Your Skin Heals 🙌

Exosomes are 30-150nm extracellular vesicles that regulate:
→ Fibroblast proliferation (collagen synthesis)
→ Angiogenesis (tissue perfusion)
→ ECM remodeling (scar reduction)
→ Inflammatory modulation (controlled healing)

exosmart™ delivers up to 30 trillion MISEV-compliant exosomes per milliliter — alongside the complete growth factor and cytokine secretome.

This is skin regeneration at the cellular signaling level. ✨

05/28/2026

🎥 Watch now: Episode 08 From Blood Draw to Injection — What Your Tuesday Morning Looks Like with exosmart™

The most practical episode in the series.
What does the exosmart™ workflow actually look like in clinic?

60ml blood. ACD-A or sodium citrate. Any centrifuge. 25-30ml combined plasma (PRP + PPP — never discard the PPP). 3-5 minutes through the cartridge. 6-7ml concentrated autologous secretome.

Draw to injection: 30 minutes.
No exogenous calcium. No thrombin. No proprietary tubes. No centrifuge dependency.

Single session by default. Second only if clinically indicated at 4-6 weeks. Maintenance at 9-12 months.

The film walks through the complete procedural choreography so there are no open questions before you start.

This is what a reproducible clinical workflow looks like.

The exosome market is exploding — but so is the gap between marketing claims and scientific evidence. ⚠️If you're evalua...
05/27/2026

The exosome market is exploding — but so is the gap between marketing claims and scientific evidence. ⚠️

If you're evaluating exosome products for your practice, ask three questions:
1️⃣ Can they prove biological identity?
A particle count alone doesn't confirm you're getting exosomes. The international standard exists for a reason.
2️⃣ What's the regulatory status?
The FDA’s position is clear and consistent. Understanding the classification matters for your practice and your patients.
3️⃣ What's the actual source?
Autologous vs. allogeneic isn’t just a technical distinction — it’s a clinical and legal one. 🔬

exosmart™ was designed to answer all three questions with evidence, not marketing. ✅
🔹 30 trillion exosomes per milliliter
🔹 MISEV-compliant markers
🔹 Complete secretome
🔹 Autologous
🔹 CE-MDR certified

Fully characterized across all three biological doses: platelets, exosomes, and secretome. 🧪

When your reputation depends on reproducible outcomes, the science behind the product matters.

👉 Swipe to see what the evidence actually requires →

SAFE | NATURAL | LASTING 💫liposmart® is designed to deliver the true potential of regenerative medicine:✓ Safe100% autol...
05/27/2026

SAFE | NATURAL | LASTING 💫
liposmart® is designed to deliver the true potential of regenerative medicine:

✓ Safe
100% autologous and CE-MDR certified for trusted clinical application.
✓ Natural
Uses your body’s own tissue — no synthetic additives, no compromise.
✓ Lasting
Focused on supporting natural regeneration, not just temporary relief.

With liposmart® UFAT, essential regenerative components remain preserved in their natural environment to support effective and minimally invasive treatments.

05/27/2026

🎥 Watch now: Episode 07 - The PRP Reckoning

The twenty-year PRP controversy is resolved. This episode explains how.
The answer wasn't in the biology. It was in the dose.

Bensa & Filardo 2025 (PMID 39751394) stratified hundreds of trials by platelet concentration. High-concentration crossed the MCID at every timepoint. Low-concentration was placebo-equivalent. Previous meta-analyses pooled both — and called the result "mixed evidence."

Patel 2024 (PMID 38410168) confirmed it: same biology per milliliter, double the volume, significantly better clinical outcomes across WOMAC, VAS, and KOOS.
The dose-response relationship is established. More biology, delivered above the threshold, produces consistent benefit.

Where exosmart™ sits:
25-30ml plasma → 6-7ml output → up to 3.0 × 10¹³ particles/ml.
Upper threshold of the clinically studied range. Where the evidence says benefit lives.
The controversy wasn't about PRP. It was about measuring the wrong thing.

05/26/2026

🎥 Watch now: Episode 06 - The Honest Advantage
This episode is built on one thesis: stating the boundaries precisely is the competitive advantage.

WHAT THE EVIDENCE SUPPORTS:
✓ 30T exosomes/ml, MISEV 2023-compliant
✓ One peer-reviewed RCT (Navarro 2025, PMID 40678344)
✓ Platform Level 1 evidence: 8 fields, 76K+ patients
✓ Dose-response relationship established

WHAT IT DOESN'T:
✗ FDA approval (none exist for any exosome product)
✗ Device-specific trials for every indication

WHY THIS MATTERS: When you name what is not yet proven, physicians trust what is proven more, not less.
AutologIX uses the same cartridge — but the published RCT was conducted with exosmart™.
ASCE+ is allogeneic. ExoCube is PRP-only. Plant-derived products are MISEV-excluded.

THE INSIGHT: Your competitors overclaim because they have to. You don't — because you have the indexed evidence.

In a field built on hype, precision is the differentiator.

05/25/2026

reposted from .grupovisao |

Regenerative orthopedics represents a new perspective in the treatment of patients with joint wear and degenerative injuries.

In Fortaleza, Dr. Eduardo Vasconcelos, an orthopedic specialist and knee surgeon, performed a procedure using exosmart™ Ortho combined with KD Intra-Articular® Gel One on a patient with significant osteoarthritis — an active patient passionate about sports, but who lived daily with pain and functional limitations.

The goal of the approach was to offer a regenerative alternative capable of supporting joint recovery by stimulating biological mechanisms involved in tissue regeneration and functional improvement, especially in patients who are not yet candidates for joint replacement surgery.

exosmart™ Ortho technology uses an advanced ultrafiltration system that concentrates components with regenerative function and removes elements without biological purpose, increasing the purity and concentration of the final autologous secretome.

Regenerative medicine expands therapeutic possibilities in orthopedics by combining science, innovation, and biological approaches focused on joint preservation and functional recovery.

05/25/2026

🎥 Watch now: Episode 05 - The Evidence Pyramid

Where does the evidence actually stand? This episode builds the pyramid — base to apex.

PLATFORM SAFETY: 76,061 patients. 8.7% adverse event rate. Lowest among injectable biologics (ESSKA 2025, PMID 41451630).

PLATFORM EFFICACY: Level 1 evidence across 8 fields. Knee OA: high-concentration PRP crosses MCID at every timepoint. Low-concentration is placebo-equivalent. The 20-year controversy, resolved (Bensa & Filardo 2025, PMID 39751394).
Lateral epicondylitis, plantar fasciitis, alopecia, diabetic ulcers, dry eye — positive. Achilles tendinopathy — negative. Disclosed with equal rigor.

DEVICE-SPECIFIC: Navarro 2025 RCT (n=30, premature ovarian insufficiency, Regenerative Therapy, PMID 40678344). Autologous exosomes: superior ovarian reserve, more oocytes, higher fertilization, positive pregnancies.
First published human RCT using autologous exosomes in reproductive medicine.

Plus two uncontrolled case series (IMCAS 2026, SEME 2025) — conference-presented, not peer-reviewed. Named as such.
Evidence transparency. From base to apex.

🎥 Stay tuned for Episode 6: The Honest Advantage

SAFE | NATURAL | LASTING ✨Why do clinicians choose liposmart® for regenerative medicine?🔬 Proven TechnologyCE-MDR certif...
05/24/2026

SAFE | NATURAL | LASTING ✨
Why do clinicians choose liposmart® for regenerative medicine?

🔬 Proven Technology
CE-MDR certified, clinically trusted, and designed for consistent, reproducible outcomes.

🌿 Natural Healing
100% autologous therapy powered by the body’s own regenerative potential.

⏱️ Fast & Efficient
Same-session, point-of-care processing completed within minutes — no laboratory required.

💉 Fluid Injectable & Minimally Invasive
Smooth and precise delivery through fine needles with minimal patient discomfort.

liposmart® UFAT (Unified Fluid Adipose Tissue) preserves the essential regenerative components that support long-lasting healing and tissue regeneration. 💪

One procedure. One system. Regeneration without compromise.
👉 Learn more via DM or visit the link in bio.

Address

Miami, FL

Alerts

Be the first to know and let us send you an email when Global Regenerative Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Global Regenerative Group:

Share